Inclusion Criteria:  Patients ≥ 18 years old, of any sex; Patients who have histopathological proof of NSCLC according to the standard of diagnosis and treatment of primary lung cancer（V2018）; Confirmed TNM stage is II-III of NSCLC; Patients who were failed, refused or assessed ineligible by MDT to receive conventional Second-Line treatments (surgery, chemoradiotherapy, targeted and immunotherapy)； Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2; Life expectancy of > 3 months; Patients volunteered to participate in this study and signed informed consent, with good compliance;  Exclusion Criteria:  Patients received interventional therapy (I seeds implantation, Ablation, BACE) before; A history combined with other malignant tumors and not cured; WBC<3×109/L、LYM<1.5×109/L、NLR≥3、PLT<50×109/L、HGB<90 g/L; Insufficient of liver and renal function (Cr>176.8 µmol/L; AST and/or ALT>2 folds of normal value)； Combined with uncorrectable coagulation dysfunction or active massive hemoptysis; Combined with active affection and need antibiotic treatment; Uncontrollable hypertension, diabetes, cardiovascular disease with obvious symptoms; Known to be hypersensitive to contrast agent; Pregnant or breastfeeding women;